Introduction
============

Inflammatory cells are a key component of the tumor microenvironment and influence the growth and progression of tumor [@B1], [@B2]. Tumor-associated macrophages (TAMs) constitute a major component of leukocyte population infiltrating tumors of the breast [@B3], [@B4]. Numerous studies have demonstrated that TAMs enhance tumor invasion, migration and angiogenesis in many solid tumors including breast cancer [@B5]-[@B7], however, with the deepening of the research, controversial conclusions have always been made.

Accumulating evidences suggests that macrophages are not a homogenous population. Thus, it should be more prudent to get a conclusion in the relationship between TAMs heterogeneity and breast cancer heterogeneity. Breast cancer is one of the few types of tumor that molecular classification has been successfully used in individualized treatment design, which can significantly improve disease specific patient survival [@B8]. Triple-negative breast cancer is negative for hormone receptors (HR) of estrogen (ER) and progesterone (PR), and human epidermal growth factor receptor-2 (HER2), and thus cannot benefit from the targeted treatment, such as Tamoxifen, Anastrozole, and Trastuzumab [@B9], [@B10]. A number of independent studies have demonstrated the correlation of TAM with ER-negativity, PR-negativity, and high mitotic rate [@B11]-[@B20]. Medrek C et al. found intensity of macrophage infiltration in tumor stoma inversely correlated with luminal A phenotype and positively correlated with triple-negative/basal-like phenotype of breast cancer [@B20]. We noticed that the association of TAMs with poor outcome was not always correct for HR/HER status or molecular subtypes. Thus, the prognostic significance of TAMs in breast cancer should be reassessed in larger cohorts separately depending on molecular classifications. The majority of triple-negative cancers are of basal-like phenotype [@B21] which has the poorest prognosis. Basal-like breast cancer (BLBC) defined by Cheang et al. [@B22] was adopted in our study.

Macrophages exhibit striking plasticity and change their physiology according to environmental cues. This lead to heterogeneous populations of specific subsets with distinct phenotype, polarization and functions [@B23], [@B24]. TAMs can be identified as two distinct states of polarized activation: the anti-tumor/pro-inflammatory M1 macrophages and the pro-tumoral/anti-inflammatory M2 macrophages [@B25], [@B26]. M1 macrophages are characterized by expressing high levels of HLADR, inducible nitric oxide synthase (iNOS) and tumor necrosis factor-α (TNF-α), and by high microbicidal and tumoricidal activity, which are associated with a better prognosis [@B27]. In contrast, M2 macrophages typically express arginase 1 (ARG1) , high levels of scavenging, mannose and galactose receptors, high levels of cytokines and chemokines that support their pro-tumoral functions [@B28]. M2 macrophages are involved in suppression of adaptive immunity, stimulation of angiogenesis, promotion of matrix remodeling and tumor invasion and migration.

In some cases, CD68^+^ TAMs were considered as a prognostic predictor in breast cancer. However, in some multivariate analyses, CD68 was not confirmed to be independent predictor of survival [@B14], [@B15], [@B17]. The most probable cause is both M1 and M2 macrophage can be stained by anti-CD68 Abs. CD163, the haemoglobin scavenger receptor, is typically expressed by TAMs and up-regulated in progressing neoplasms. In many studies, CD163 is regarded as a highly specific marker for M2-like polarized macrophages [@B29]-[@B32]. Some studies proved that CD163^+^ TAMs was more closely related to unfavorable clinicopathological features in breast cancer [@B20]. However, to our knowledge no paper has reported the presence and prognostic significance of CD68^+^ and CD163^+^ macrophages in the basal-like subset of breast cancer by molecular classification. Therefore, the aim of this study was to investigated the extent of infiltration and distribution patterns of macrophages in BLBC, to compare TAMs labeled by CD163 with those identified by the more frequently used pan-macrophage marker CD68, and to determine their association with clinicopathological features and prognostic value in BLBC.

Materials and Methods
=====================

Patients
--------

We included 200 cases of BLBC from 1,971 contiguous cases of invasive breast cancer diagnosed at the Department of Pathology, Tianjin Medical University Cancer Hospital (Tianjin, China), between April 2006 and December 2007. Neoadjuvant therapy (NAT) will seriously affect the immune cells including TAMs in the tumor microenvironment, so all the patients selected in this study are BLBC patients who did not receive NAT before surgery. And we chose BLBCs that contain only IDC-NOS, which have relatively uniform molecular and pathological features (CONSORT diagram, Fig. [1](#F1){ref-type="fig"}). The patients were followed up for 12-86 months (median, 66 months), and the range of the patients age at the time of diagnosis was 26-81 years (median, 51 years). During the follow-up, 42 (21%) patients died of cancer, and 66 patients (33%) developed a breast cancer recurrence, included 9 (4.5%) with local or regional tumor recurrence and 57 (28.5%) with distant metastasis. All the patients underwent modified radical mastectomy or breast-conserving surgery with axillary lymph node dissection. Postoperatively, all the patients received adjuvant chemotherapy and 156 (78%) received radiation therapy. All patients signed an informed consent form for the use of their biological tissues in the study. The study was reviewed and approved by the Institutional Ethics Committee of Tianjin Medical University Cancer Institute and Hospital, Tianjin, China (No. bc2015005).

Immunohistochemistry
--------------------

Formalin-fixed, paraffin-embedded serial tissue sections of full block-face tissue from surgical specimen of each case were selected for CD68^+^ and CD163^+^ immunohistochemical stains using standard procedures. Briefly, 4µm tissue sections were subsequently dewaxed and rehydrated using xylene and graded alcohol washes. Antigen retrieval was performed at 121^o^C for 2 min, using citrate buffer, pH 6.0. After serial blocking with hydrogen peroxide and normal goat serum, the sections were incubated with primary polyclonal antibody against CD68 (Abcam, ab213096, monoclonal \[KP1\], 0.5µg/ml) and CD163 (Abcam, ab74604, monoclonal \[10D6\]) for 30 min at room temperature. Then, the sections were sequentially incubated with biotinylated goat anti-mouse immunoglobulin and peroxidase-conjugated streptavidin.

TAMs were scored as the infiltration density of CD68^+^ or CD163^+^ cells with a monocyte/macrophage morphology with oval or rounded nuclei that showed strong membranous or cytoplasmic staining. In this study, TAMs in tumor nest (TN) is defined as the intraepithelial tumor-infiltrating macrophages. The definition of \'tumor stroma (TS)\' in this study is the fibrous tissue surrounding tumor nest (Fig. [2](#F2){ref-type="fig"}); the lymphoid infiltrates surrounding the tumor bed are excluded. TAMs were evaluated by adapting the reported hotspot quantitative method.[@B17], [@B18], [@B33]-[@B36] The entire stained section was first scanned at low magnification (×100) to identify the hotspot areas (five areas of TN and five areas of TS) with most abundant macrophages. The average count of macrophages in all five areas and the density of infiltration was estimated (per 0.24mm^2^) at higher magnification (×400). For statistical analyses, the density of CD163^+^ macrophages in the TS were dichotomized into low (0-36 macrophages/0.24mm^2^) and high infiltration (\>36 macrophages/0.24mm^2^) according to the median (Table [1](#T1){ref-type="table"}). CD68^+^ macrophages in the TS were also scored by this critical value to unify the scoring criteria. Similarly, the density of CD163 in the TN was denoted as low (0-11 macrophages/0.24mm^2^) and high (\>11 macrophages/0.24mm^2^) according to the median (Table [1](#T1){ref-type="table"}), and the density of CD68 in the TN was also assessed by this critical value. Two researchers (pathologists) blinded to the clinical information carried out the evaluation process.

Additional immunohistochemistry was performed on serial tissue sections for molecular sub-classification of the tumors. Primary antibodies against ER (clone SP1, 1:150 dilution, Zymed, San Francisco, CA), PR (clone SP2, 1:150 dilution, Zymed), and HER2 (DAKO HercepTestTM, Denmark,), Ki-67 (clone SP6, 1:200 dilution, ThermoScientific, Fremont CA), EGFR (clone 31G7, 1:100 dilution, Zymed), and CK5/6 (clone D5/16B4, 1:100 dilution, Zymed) were applied according to manufacturer\'s instructions. Interpretation and scoring of ER, PR, HER2, Ki-67, EGFR, and CK5/6 staining described by Cheang et al. [@B22] was adopted in our study. Basal-like breast cancer was defined as ER negative, PR negative, HER2 negative, and EFGR and/or CK5/6 positive. Confirmatory fluorescence in situ hybridization (FISH) evaluation using Vysis kit (Vysis, Inc., Downers Grove, IL) was pursued on those tumors with a 2^+^ HER2 expression by immunohistochemistry. The interpretation was based up the manufacture guideline.

Statistical Analysis
--------------------

Spearman\'s Rho test was used to examine whether the expression levels of CD68 and CD163 in macrophages were associated with clinicopathological characteristics. Wilcoxon Signed Ranks Test was performed for comparing macrophages between different tissue locations. Overall survival (OS) was measured from the date of curative surgery to the date of breast cancer-specific death. Recurrence-free survival (RFS) was measured from the date of curative surgery to the date of breast cancer recurrence, regardless of whether recurrence was local or regional, and/or distant metastasis. Kaplan-Meier analysis and long-rank tests were performed to identify the difference in OS and RFS according to CD68^+^ and CD163^+^ macrophage infiltration. Cox regression proportional hazards models were performed to estimate the hazard ratios (HR) for RFS and OS of BLBC according to CD68^+^ and CD163^+^ macrophage infiltration in univariate and multivariate models. A two-sided *P*\<0.05 was considered significant. Statistical analysis was performed with SPSS 19.0 software (SPSS, IBM).

Results
=======

Characterization of CD68^+^ and CD163^+^ macrophages in BLBC
------------------------------------------------------------

As shown in Fig. [2](#F2){ref-type="fig"}, CD68^+^ macrophages and CD163^+^ macrophages were present in both TS and TN of BLBC. We evaluated the macrophages in TS and TN separately and found significantly more macrophages infiltrated in TS than in TN (CD68: median 40 *vs.* 13; *Z*=-11.725, *p*\<0.001; CD163: median 36 *vs.* 11; *Z*=-10.665, *p*\<0.001; Table [1](#T1){ref-type="table"} and Fig. [2](#F2){ref-type="fig"}). The ratio of TN/total (CD68: median 0.24; CD163: median 0.24) and TS/Total (CD68: median 0.72; CD163: median 0.73) were also shown in Table [1](#T1){ref-type="table"}. There was a strong correlation between CD163 and CD68 in both TS (*r~s~*=0.404, *p*\<0.001) and TN (*r~s~*=0.621, *p*\<0.001). No correlation was identified between the infiltration density of CD163^+^ macrophages in the TS and in the TN (*r~s~*=0.060, *p*=0.399) (Table [1](#T1){ref-type="table"}), while a significant correlation between the infiltration density of CD68^+^ macrophages in the TS and in the TN (*r~s~*=0.275, *p*\<0.001) (Table [1](#T1){ref-type="table"}) was identified.

Correlations of CD68^+^ and CD163^+^ macrophages to clinicopathological features
--------------------------------------------------------------------------------

High infiltrations of CD68^+^ macrophage and CD163^+^ macrophage in the TS were both positively associated with larger tumor size (*r~s~*=0.203, *p*=0.004; *r~s~*=0.284, *p*\<0.001, respectively), higher histological grade (*r~s~*=0.153, *p*=0.030; *r~s~*=0.581, *p*\<0.001, respectively), higher 5-year recurrence rate (*r~s~*=0.217, *p*=0.002; *r~s~*=0.145, *p*=0.041, respectively) and higher 5-year breast cancer mortality (*r~s~*=0.215, *p*=0.002; *r~s~*=0.178, *p*=0.011, respectively). Higher density of CD163^+^ macrophage (*r~s~*=-0.380,*p*\<0.001), but not CD68^+^ macrophage (*r~s~*=-0.124, *p*=0.080), in the TS was observed in tumors of younger patients. There was no significant association between stromal CD68^+^ and CD163^+^ macrophage infiltration and lymph node metastasis (*r~s~*=0.130, *p*=0.067; *r~s~*=0.029, *p*=0.688, respectively) (Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). In contrast, neither CD68^+^ macrophages nor CD163^+^ macrophages in the TN was found significantly correlated with any of the above clinicopathological features (*p*\>0.05; Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

Prognostic significance of CD68^+^ macrophages and CD163^+^ macrophages
-----------------------------------------------------------------------

Univariate Cox proportional hazards regression analysis identified that the high density of CD68^+^ and CD163^+^ macrophage infiltration in TS was associated with poor OS (HR=2.985, *p*=0.005; HR=3.548, *p*\<0.001) and RFS (HR=2.229, *p*=0.005; HR=3.975, *p*\<0.001) (Table [4](#T4){ref-type="table"}; Fig. [3](#F3){ref-type="fig"}). In contrast, there was no correlation between CD68^+^ or CD163^+^ macrophages in TN with OS (HR=0.951, *p*=0.870; HR=1.322, *p*=0.371) and RFS (HR=0.925, *p*=0.753; HR=1.496, *p=*0.108) (Table [4](#T4){ref-type="table"}; Fig. [3](#F3){ref-type="fig"}).

Multivariate Cox proportional hazards regression analysis, after adjusting for patient age, tumor size, histological grade, lymph node stage and radiotherapy, proved CD163^+^ macrophages in TS, but not CD68^+^ macrophages, was an independent prognostic factor for worse OS (HR=3.427, *p*=0.009) and RFS (HR=4.304, *p*\<0.001) (Table [5](#T5){ref-type="table"}).

Discussion
==========

Macrophages are heterogeneous subsets with different functions. CD68 has been used to recognize tumoricidal M1 and pro-tumoral M2 macrophages. Even though multiple clinical studies had evidenced that CD68^+^ macrophage positively associated with high vascularity and nodal metastasis and negatively correlated with RFS and OS in breast cancer, as a pan-macrophage marker, CD68 was found not an independent predictor of OS in some multivariate analyses [@B14], [@B15], [@B17]. A prior study using tissue microarrays (TMAs) with a large sample size suggests that overall numbers of CD68^+^ macrophages are not related to prognosis in breast cancer [@B15]. These results demand further investigation to identify the subset of TAMs that may service as the prognosis-related biomarkers. Meanwhile, CD163, a highly specific biomarker for M2 macrophages [@B29], [@B32], was found to be closely correlated with unfavorable clinicopathological characters in some study.[@B20] It has been recently found that BLBC hosts more TAMs infiltration, particularly the CD163^+^ cells, than other types of breast cancers [@B20]. However, the study with a small number of BLBC cases did not explore the prognostic significance of CD68^+^ and CD163^+^ macrophages in BLBC. We therefore undertook the study to evaluate the infiltration of stromal and intraepithelial CD68^+^ macrophages along with the identification of CD163^+^ macrophages to assess their prognostic value in a larger BLBC cohort. In addition, TAMs in different intratumoral regions are subsets with distinct molecular and functional features, and thus may exhibit different prognostic values. Unfortunately, limited studies have considered the locations in the evaluation of clinical significance. Although three studies (two by marker of CD68 [@B15], [@B33] and one by markers of CD68 and CD163 [@B20]) in human breast cancer have included the locations of TAMs, two of which used the TMA samples to put it into practice [@B15], [@B20]. We used full block-face tissue sections in the study to overcome the limitation of core materials that only contain small volume of tumor tissue may suffer from bias in the assessment of TAMs due to tumor heterogeneity. Full block-face tissue sections allow the selection of tumor areas with abundant TAMs for accurate scoring in tumor nest and in tumor stroma separately.

In this cohort of BLBC, CD68^+^ or CD163^+^ macrophages in TN was not found to be correlated with any of the clinicopathological features, OS or RFS. Medrek et al. recently also found no correlations between clinicopathological features and CD68^+^ or CD163^+^ macrophage infiltrates in tumor nest, and the same relationship with RFS and OS was also noted [@B20]. Mahmoud et al. reported that intratumoural CD68^+^ macrophage did not correlate with breast cancer-specific survival [@B15]. Although the methods and molecular subtypes of breast cancer patients were different in these studies, the results suggest that the TAMs infiltrates into tumor nest is not an important prognostic factor for patient outcome.

TAM promotes tumor progression through several mechanisms [@B37]. In contrast to TN, the study found that increased CD68^+^ or CD163^+^ macrophages in TS were correlated with larger tumor size, higher histological grade, and worse RFS and OS. It suggested that TAMs may affect the prognosis of BLBC mainly through modulating the immune response by contacting with tumor-infiltrating lymphocytes in TS, rather than through the direct interaction between macrophages and cancer cells in TN, such as phagocytosis of cancer cells. However, the specific underlying mechanisms need further study. It is worthy of notice that although univariate analysis identified the total TAM infiltrates in TS was associated with poor RFS and OS in BLBC, multivariate analysis only proved CD163^+^ macrophages in TS was an independent predictor of RFS and OS. We also got similar conclusions in multivariate Cox regression analyses using continuous variables, one-quarter and median as the cutoffs, i.e., CD163^+^ macrophages in TS was an independent prognostic factor for worse OS and RFS (Supplementary Table [1](#SM0){ref-type="supplementary-material"}). It indicates that in contrast to the pan-macrophage marker CD68, macrophages expressing the anti-inflammatory CD163 marker (M2 macrophages) are probably the effect TAMs that facilitate the poor prognosis of BLBC and serve as an independent prognostic predictor.

A number of potential macrophage-centred therapeutic strategies are being explored [@B37]. Either manipulating TAMs localization at tumor sites, or targeting the signal pathways affecting TAMs polarization and functions is proved to improve the outcomes of breast cancer [@B38]. The pro-tumor M2 macrophage, recognized by CD163, is reversible [@B39], [@B40]. Duluc et al. used INF-γ to reverse the immunosuppressive and pro-tumoral foundations and prevent the generation of M2 macrophage [@B41]. Similar to the result, Guiducci et al. activated TLR9 by its ligand CpG, along with antibody to IL-10, and switched TAMs from an M2 macrophage to an M1 macrophage [@B42]. And classically activated M1 macrophage can kill cancer cells and induce tumor-destructive reaction [@B43]. Therefore, blocking key molecular determinants of macrophage polarization may result in reorientation of macrophage polarization and activate the anti-tumor activity [@B39], [@B44], [@B45]. In a preclinical glioma model, a small molecule agent BZL945 (CSF‑1R inhibitor) improved the survival by \'re‑education\' of macrophages from a protumor M2‑like phenotype to an antitumor M1‑like type instead of TAM number depletion [@B46]. Although TAM-centered strategies have not been yet introduced in clinical practice in terms of effectiveness and tolerability in breast cancer patients, reducing number or reeducating of TAM seems to be a promising strategy and should be further investigated due to its clinical significance in BLBC.

There are limitations in the study. Although CD163 was regarded as a highly special M2 macrophage marker, it can also be expressed by monocyte-derived dendritic cells (MDCs) [@B47]. Medrek C et al. observed some CD163^+^ areas lacked CD68 expression. They attributed this to a CD163-expressing subset of immature myeloid derived suppressor cells with prognostic impact although no direct data was available [@B20]. Thus, we cannot exclude MDCs cells or myeloid derived cells expressing CD163, which could have impact on the poor prognosis trigged by CD163^+^ macrophage in BLBC. It is warranting to further clarify the phenotype of TAMs and the significant impact of M1/M2 macrophage ratio on the clinical course of BLBC patients. Few specific markers are so far available, and therefore there is still an urgent need to identify markers specific for M1/M2 macrophage. Some other TAM-related biomarkers that have been explored include CD206, VEGF, HIFs, TFL, PCNA and CCL18 [@B4]. Further investigation to identify their roles in sub-classifying TAMs into different prognosis-related biological groups will be meaningful and will be one of the focuses of our future studies.

Conclusion
==========

This study identified that infiltration of CD68^+^ or CD163^+^ macrophages in TS, not the TN, is associated with the clinicopathological features of BLBC and worse prognosis of patients. CD163^+^ macrophages in TS, instead of CD68^+^ macrophage, is proven to an independent risk factor for worse RFS and OS. TAMs signature is a promising therapeutic target in BLBC. However, further work is still warranting to validate the findings.
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![CONSORT diagram.](jcav09p2308g001){#F1}

![The density and distribution pattern of macrophage infiltration characterized by CD68 and CD163 immunoreactivity in the tumor nest (TN) and tumor stroma (TS) of BLBC. **A-B** Representative images of high density of CD68^+^ staining (**A**) and CD163 staining (**B**) in TN and TS. **C-D** Representative images of low density of CD68^+^ staining (**C**) and CD163 staining (**D**) in TN and TS. Scale bar, 100 μm](jcav09p2308g002){#F2}

![RFS and OS curves based on macrophage properties.**A-D** Recurrence-free survival and Overall survival curves by CD68-positive macrophage infiltration into the tumor nest**(A, C)** and stroma **(B, D)**. **E-H** Overall survival curves by CD163-positive M2 macrophage infiltration into the tumor nest**(E, G)** and stroma **(F, H)**.](jcav09p2308g003){#F3}

###### 

Distribution pattern of TAMs in BLBC

  Variables                 Mean^a^   SE^a^   Median^a^   Range^a^    *Z*^b^    *P*^b^    *r~s~*^c^   *P*^c^
  ------------------------- --------- ------- ----------- ----------- --------- --------- ----------- ---------
  **CD68^+^ macrophage**                                              -11.725   \<0.001   0.275       \<0.001
  Tumor nest                15        1.01    13          2-79                                        
  Tumor stroma              46        2.56    40          5-197                                       
  **CD163^+^ macrophage**                                             -10.665   \<0.001   0.060       0.399
  Tumor nest                14        0.92    11          1-75                                        
  Tumor stroma              42        2.09    36          3-184                                       
  **TN/total**                                                                                        
  CD68^+^ macrophage        0.23      0.01    0.24        0-0.63                                      
  CD163^+^ macrophage       0.25      0.01    0.24        0-0.61                                      
  **TS/Total**                                                                                        
  CD68^+^ macrophage        0.72      0.01    0.72        0.38-1                                      
  CD163^+^ macrophage       0.74      0.01    0.73        0.35-0.94                                   

^a^ Cell count per field (cells/0.24 mm^2^)

^b^ Wilcoxon signed ranks test

**^c^**Spearman\'s Rho test

###### 

Correlations between CD68^+^ macrophages and clinicopathological features in BLBC by their locations

  ------------------------------------------------------------------------------------------------------
                                       CD68 in TS            CD68 in TN                          
  ------------------------------ ----- ------------ -------- ------------ -- ---------- -------- -------
  **Age, years**                                    -0.124   0.080                      -0.061   0.388

  \< 50                          98    62(63.3)                              55(56.1)            

  ≥50                            102   52(51.0)                              51(50.0)            

  **Tumor size, cm**                                0.203    0.004                      0.061    0.389

  ≤2                             60    25(41.7)                              29(48.3)            

  \> 2                           140   89(63.6)                              77(55.0)            

  **Histological Grade (SBR)**                      0.153    0.030                      0.037    0.608

  Grade 1                        0     0                                     0                   

  Grade 2                        94    46(48.9)                              48(51.1)            

  Grade 3                        106   68(64.2)                              58(54.7)            

  **Lymph node metastasis**                         0.130    0.067                      0.002    0.978

  Negative                       123   63(51.2)                              67(54.5)            

  1 to 3                         43    30(69.8)                              19(44.2)            

  4 to 9                         22    14(63.6)                              8(36.4)             

  10 or more                     12    7(58.3)                               12(100)             

  **Recurrence (5 years)**                          0.217    0.002                      0.041    0.568

  No                             156   80(51.3)                              81(51.9)            

  Yes                            44    34(77.3)                              25(56.8)            

  **Breast cancer mortality**\                      0.215    0.002                      0.022    0.758
  **(5 years)**                                                                                  

  No                             162   84(51.9)                              85(52.5)            

  Yes                            38    30(78.9)                              21(55.3)            
  ------------------------------------------------------------------------------------------------------

TS, tumor stroma; TN, tumor nest; BLBC, basal-like breast cancer.

###### 

Correlations between CD163^+^ macrophages and clinicopathological features in BLBC by their locations

  --------------------------------------------------------------------------------------------------------
                                       CD163 in TS            CD163 in TN                          
  ------------------------------ ----- ------------- -------- ------------- -- ---------- -------- -------
  **Age, years**                                     -0.380   \<0.001                     -0.100   0.159

  \< 50                          98    68(69.4)                                54(55.1)            

  ≥50                            102   32(31.4)                                46(45.1)            

  **Tumor size, cm**                                 0.284    \<0.001                     0.022    0.759

  ≤2                             60    17(28.3)                                29(48.3)            

  \> 2                           140   83(59.3)                                71(50.7)            

  **Histological Grade (SBR)**                       0.581    \<0.001                     -0.020   0.778

  Grade 1                        0     0                                       0                   

  Grade 2                        94    18(19.1)                                48(51.1)            

  Grade 3                        106   82(77.4)                                52(49.1)            

  **Lymph node metastasis**                          0.029    0.688                       0.011    0.872

  Negative                       123   58(47.2)                                62(50.4)            

  1 to 3                         43    29(67.4)                                19(44.2)            

  4to 9                          22    8(36.4)                                 11(50.0)            

  10 or more                     12    5(41.7)                                 8(66.7)             

  **Recurrence (5 years)**                           0.145    0.041                       0.072    0.308

  No                             156   72(46.2)                                75(48.1)            

  Yes                            44    28(63.6)                                25(56.8)            

  **Breast cancer mortality**\                       0.178    0.011                       0.051    0.473
  **(5 years)**                                                                                    

  No                             162   74(45.7)                                79(48.8)            

  Yes                            38    26(68.4)                                21(55.3)            
  --------------------------------------------------------------------------------------------------------

TS, tumor stroma; TN, tumor nest; BLBC, basal-like breast cancer.

###### 

Univariate Cox regression analyses for RFS and OS of BLBC

  Variables                               OS                     RFS                                     
  --------------------------------------- ------- -------------- ------------- -- ------- -------------- -------------
  **Age** (\<50 *vs*.≥50)                 1.937   0.277-0.973    **0.038**        1.472   0.401-1.149    0.150
  **Tumor size, cm** (≤2 *vs*. \>2)       4.999   1.782-14.023   **0.002**        4.314   2.055-9.054    **\<0.001**
  **Histological Grade** (II *vs.* III)   1.105   0.599-2.040    0.749            1.235   0.753-2.026    0.402
  **Lymph node stage** (N0 *vs.* N1-3)    1.932   1.490-2.504    **\<0.001**      1.929   1.573-2.366    **\<0.001**
  **Radiotherapy** (no *vs.* yes)         3.606   2.043-6.364    **\<0.001**      5.755   3.217-10.294   **0.000**
  **CD68^+^ in TS** (low *vs.* high)      2.985   1.381-6.449    **0.005**        2.229   1.269-3.914    **0.005**
  **CD163^+^ in TS** (low *vs.* high)     3.548   1.697-7.417    **\<0.001**      3.975   2.200-7.180    **\<0.001**
  **CD68^+^ in TN** (low *vs.* high)      0.951   0.519-1.742    0.870            0.925   0.571-1.500    0.753
  **CD163^+^ in TN** (low *vs.* high)     1.322   0.717-2.436    0.371            1.496   0.916-2.445    0.108

BLBC, basal-like breast cancer; TS, tumor stroma; TN, tumor nest; OS: overall survival; RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval.

###### 

Multivariate Cox regression analyses for RFS and OS of BLBC

  Variables                               OS                    RFS                                    
  --------------------------------------- ------- ------------- ------------- -- ------- ------------- -------------
  **Age** (\<50 *vs*.≥50)                 2.463   0.184-0.897   **0.026**        2.032   0.244-0.991   **0.047**
  **Tumor size, cm** (≤2 *vs*. \>2)       3.020   1.030-8.854   **0.044**        2.581   1.192-5.588   **0.016**
  **Histological Grade** (II *vs.* III)   1.435   0.647-3.180   0.374            1.367   0.722-2.588   0.338
  **Lymph node stage** (N0 *vs.* N1-3)    1.748   1.311-2.331   **\<0.001**      1.836   1.468-2.297   **\<0.001**
  **Radiotherapy** (no *vs.* yes)         1.328   0.938-1.882   0.110            1.190   0.906-1.564   0.212
  **CD68^+^ in TS** (low *vs.* high)      1.850   0.796-4.298   0.153            1.250   0.666-2.345   0.487
  **CD163^+^ in TS** (low *vs.* high)     3.427   1.368-8.587   **0.009**        4.304   1.994-9.286   **\<0.001**

BLBC, basal-like breast cancer; TS, tumor stroma; OS: overall survival; RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval.
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